Esperion's lead candidate shows promise in Type 2 diabetes
This article was originally published in Scrip
Executive Summary
Esperion has announced positive Phase II top line results for its hypercholesterolemia product, ETC-1002, in type 2 diabetes. The Plymouth, Michigan-based firm plans to advance the drug through Phase II development and explore the product's efficacy in additional patient populations, particularly those intolerant of statins.